L-Methylfolate as Adjunctive Therapy for SSRI-Resistant Major Depression: Results of Two Randomized, Double-Blind, Parallel-Sequential Trials

George I. Papakostas, M.D.
Richard C. Shelton, M.D.
John M. Zajecka, M.D.
Bijan Etemad, M.D.
Karl Rickels, M.D.
Alisabet Clain, M.S.
Lee Baer, Ph.D.
Elizabeth D. Dalton, B.A.
Garret R. Sacco, B.A.
David Schoenfeld, Ph.D.
Michael Pencina, Ph.D.
Allison Meisner, M.A.
Teodoro Bottiglieri, Ph.D.
Erik Nelson, M.D.
David Mischoulon, M.D., Ph.D.
Jonathan E. Alpert, M.D., Ph.D.
James G. Barbee, M.D.
Sidney Zisook, M.D.
Maurizio Fava, M.D.

Objective: The authors conducted two multicenter sequential parallel comparison design trials to investigate the effect of L-methylfolate augmentation in the treatment of major depressive disorder in patients who had a partial response or no response to selective serotonin reuptake inhibitors (SSRIs).

Method: In the first trial, 148 outpatients with SSRI-resistant major depressive disorder were enrolled in a 60-day study divided into two 30-day periods. Patients were randomly assigned, in a 2:3:3 ratio, to receive L-methylfolate for 60 days (7.5 mg/day for 30 days followed by 15 mg/day for 30 days), placebo for 30 days followed by L-methylfolate (7.5 mg/day) for 30 days, or placebo for 60 days. SSRI dosages were kept constant throughout the study. In the second trial, with 75 patients, the design was identical to the first, except that the L-methylfolate dosage was 15 mg/day during both 30-day periods.

Results: In the first trial, no significant difference was observed in outcomes between the treatment groups. In the second trial, adjunctive L-methylfolate at 15 mg/day showed significantly greater efficacy compared with continued SSRI plus placebo on both primary outcome measures (response rate and degree of change in depression symptom score) and two secondary outcome measures of symptom severity. The number needed to treat for response was approximately six in favor of adjunctive L-methylfolate at 15 mg/day. L-Methylfolate was well tolerated, with rates of adverse events no different from those reported with placebo.

Conclusions: Adjunctive L-methylfolate at 15 mg/day may constitute an effective, safe, and relatively well tolerated treatment strategy for patients with major depressive disorder who have a partial response or no response to SSRIs.

(Am J Psychiatry 2012; 169:1267-1274)

Evidence began to accumulate for an association between folate-deficiency states and depression soon after clinically reliable assays for folate became widely available in the 1960s (1–9). In addition to studies suggesting a relationship between low folate levels and an elevated risk for major depressive disorder, there is also accumulating evidence to suggest that low folate levels in patients with major depression may predict poorer prognosis during treatment (3, 10–15). These studies have in turn attracted the interest of the research community regarding the use of folate as a potential treatment for major depression. To date, several clinical studies have examined the use of folic acid or various folic acid metabolites (16–23) as monotherapy or as adjunctive therapy for major depression.

Despite the progressive development of dozens of antidepressant agents, more than half of all patients treated with antidepressant monotherapy will fail to experience a remission of their major depressive episode (24). Thus, developing safe, well-tolerated, and effective treatments that would help bring about remission in patients with antidepressant-resistant major depression is of paramount importance. In light of studies suggesting the potential efficacy, safety, and tolerability of L-methylfolate as an adjunct to standard antidepressants (19, 20), it may represent a unique opportunity for novel treatment development in major depression. L-Methylfolate is the biologically active form of folate and the only form of folate that crosses the blood-brain barrier. L-Methylfolate also

This article is featured in this month’s AJP Audio, is an article that provides Clinical Guidance (p. 1274), and is discussed in an Editorial by Dr. Nelson (p. 1223)

Am J Psychiatry 169:12, December 2012 ajp.psychiatryonline.org 1267
regulates the formation of a critical cofactor for neurotransmitter synthesis, tetrahydrobiopterin (BH4). BH4 in turn activates tryptophan hydroxylase and tyrosine hydroxylase, which are necessary and rate-limiting enzymes for the synthesis of three monoamines: serotonin, dopamine, and norepinephrine. Because l-methyfolate indirectly regulates monoamine levels, low CNS levels of l-methyfolate could lead to monoamine deficiency. Until recently, randomized, double-blind, placebo-controlled trials focusing on the use of l-methyfolate as adjunctive therapy for antidepressant-resistant major depression were lacking. Here we report on the outcome of two separate trials of l-methyfolate as an adjunct to a selective serotonin reuptake inhibitor (SSRI), identical in design except for differences in dosing. In order to enhance our study's statistical power to detect a difference in antidepressant effect between drug and placebo, the sequential parallel comparison design (25) was selected as the study design for our clinical trials.

Method

Trial 1

Study design. The first trial was a 60-day, multicenter (11 clinical sites in the United States), randomized, double-blind, sequential parallel comparison trial of adjunctive l-methyfolate for SSRI-resistant major depressive disorder. Institutional review board-approved written informed consent was obtained from all study patients before any study procedures were conducted. Eligibility was assessed primarily during the screening visit and secondarily during the baseline visit, which occurred 14 days after the screening visit. Patient inclusion and exclusion criteria were as follows: being 18-65 years of age; meeting DSM-IV criteria for current major depressive disorder during the screening and baseline visit, as assessed by the Structured Clinical Interview for DSM-IV Axis I Disorders (26); having a score ≥12 on the Quick Inventory of Depressive Symptomatology—Self-Rated (QIDS-SR) (24) at both screening and baseline visits; having received treatment with an SSRI at adequate dosages (defined as ≥20 mg/day of fluoxetine, citalopram, or paroxetine; ≥10 mg/day of escitalopram, or ≥50 mg/day of sertraline) during the current episode for at least 8 weeks, as assessed historically using the Massachusetts General Hospital Antidepressant Treatment Response Questionnaire (which measures historical, not prospective antidepressant use); and having been on a stable dose of SSRI for the past 4 weeks at the baseline visit. Exclusion criteria were breastfeeding, pregnancy, or being child-bearing age and not using a medically accepted means of contraception; demonstrating >25% decrease in depressive symptom severity as reflected by the QIDS-SR total score between screening and baseline; having a serious suicide or homicide risk or an unstable medical illness as assessed by the evaluating clinician; having an active substance use disorder within the past 6 months; having a history of mania, hypomania (including antidepressant-induced), psychotic symptoms, or seizure disorder; showing clinical evidence of untreated hypothyroidism; having failed to experience sufficient symptom improvement after more than two antidepressant trials during the current major depressive episode; and taking vitamins or dietary supplements containing >400 μg of folate or >6 μg of vitamin B12.

Study procedures. Patients who were found eligible during the baseline visit were enrolled in the study according to a format of the sequential parallel comparison design (25), and eligible patients were randomized to one of three treatment groups in a 2:3:3 ratio. The study was divided into two 30-day phases (phases 1 and 2). One group of patients (randomization probability 3:8) received two dummy pills identical to l-methyfolate in appearance during phases 1 and 2 (placebo-placebo group). The second group (randomization probability 3:8) received two dummy pills during phase 1 and one dummy pill and one 7.5-mg l-methyfolate pill during phase 2 (placebo-drug group). The third group (randomization probability 2:8) received one dummy pill and one 7.5-mg l-methyfolate pill during phase 1 and two 7.5-mg l-methyfolate pills during phase 2 (drug-drug group). This format of the sequential parallel comparison design was selected instead of the one (25) involving a randomization to drug and placebo in phase 1 and a re-randomization of placebo nonresponders to drug or placebo in phase 2.

Postbaseline study visits occurred every 10 days. SSRI dosages remained constant during phases 1 and 2 of the study. Participants unable to tolerate the study medications as per protocol were withdrawn from the study.

The 17-Item Hamilton Depression Rating Scale (HAM-D) (27), QIDS-SR, and Clinical Global Impressions (CGI) severity and improvement scales (28) were administered during all postscreen visits.

Trial 2

The results of the first trial were available to the investigators and sponsor prior to, and were informative in the development of the design of, the second trial. In the first trial, 7.5 mg/day of adjunctive l-methyfolate did not appear to result in superior treatment outcome (efficacy) than continued antidepressant therapy plus placebo. However, among patients who did not respond to 7.5 mg/day of l-methyfolate in phase 1 but whose dosage of l-methyfolate was increased to 15 mg/day in phase 2, the response rates in phase 2 were greater than in patients who continued on antidepressant monotherapy and adjunctive placebo (24.0% compared with 9%), although the difference fell short of statistical significance (p=0.1). Given the possibility of a better response with a longer trial of l-methyfolate, the target dose for the second trial was set at 15 mg/day.

The design of the second trial was identical to the first except that the dosing of l-methyfolate was 15 mg throughout the trial for all patients receiving it (those assigned to the placebo-drug group and to the drug-drug group). Six clinical sites participated in the second trial, and all were selected from the 11 sites that participated in the first trial based on their demonstrated ability to enroll the target patients in a reasonable time frame during the first trial. Institutional review board-approved written informed consent was obtained from all study patients before any study procedures were conducted.

General Statistical Considerations

The two primary outcome measures for both studies were defined as the difference in response rates according to the HAM-D and in degree of improvement in HAM-D score between the two treatment groups. Response according to the HAM-D was defined as a reduction of ≥50% in HAM-D score during treatment (or a final score ≤7). The Hochberg-Benjamini approach (29) was used to control for multiple testing. According to this approach, the trial can be declared a success if one of the two primary outcome measures is significant at the 0.025 level or if both are significant at the 0.05 level. The sample sizes of the two studies were selected based on power calculations with specific assumptions about response rates in the two phases, according to the analytical method described in Fava et al. (25) for the sequential parallel comparison design. Secondary outcome measures included continuous change in scores on the QIDS-SR and CGI severity scale during treatment. Additional
secondary outcome measures included the proportion of patients who met response criteria according to the QIDS (a reduction of ≥50% in QIDS score during treatment or a final score ≤5), remission status according to the QIDS (a final score ≤5), or remission status according to the HAM-D (a final score ≤7).

**Sequential Parallel Comparison Design Analytic Model**

The traditional analytical approach for standard antidepressant clinical trials has been to compare the difference in symptom improvement during treatment with a drug and with placebo for all patients randomized to treatment (intent-to-treat approach), defining endpoint symptom severity for patients who prematurely discontinue treatment as the last available depression severity score (last observation carried forward).

The format of the sequential parallel comparison design approach used in this study, however, was conducted as follows:

1. A standard intent-to-treat/last-observation-carried-forward approach was employed for patients treated with drug during phase 1.
2. The phase 2 data set of interest was limited to patients treated with placebo during phase 1 who completed phase 1 without experiencing a clinical response according to the HAM-D and entered phase 2.
3. The last-observation-carried-forward approach was applied to the sequential parallel comparison design analysis data set for phase 2, with the final visit of phase 1/first visit of phase 2 serving as the new baseline visit. Drug was compared with placebo in phase 2 for this patient subset alone.
4. The intent-to-treat/last-observation-carried-forward data comparing drug and placebo during phase 1 (see step 1 above) was combined with the data comparing drug and placebo according to the sequential parallel comparison design model for phase 2 (steps 2 and 3 above) and analyzed using the statistical model described by Fava et al. (25) using a weight and a randomization fraction chosen to maximize the power of the test. When calculating the pooled treatment effect from treatment effects obtained in phases 1 and 2, equal weights were given for each phase.

In the first trial, only the 7.5-mg/day arms were designed to be comparable to placebo. Thus, the 15-mg/day arm was not pooled with the 7.5-mg/day arms when calculating efficacy analyses.

Dichotomous measures were analyzed according to the sequential parallel comparison design method for dichotomous outcomes as described by Fava et al. (25), while the "seemingly unrelated regressions model," controlling for baseline scores, was employed for the comparison of continuous outcomes according to the method of Tamura and Huang (30). Equal weights of 0.5 for each phase were selected before the analyses were conducted to avoid more arbitrary or data-driven choices. For the comparison of adverse events between groups, the chi-square test was used. All tests were two-tailed, with alpha set at 0.05 (no adjustments for multiple comparisons). Safety and tolerability analyses were conducted based on all data available (all patients randomized, all study visits).

**Power Calculations**

For the first trial, assuming a difference in response rates in drug versus placebo of 0.375 versus 0.20 in phase 1 and 0.25 versus 0.10 in phase 2, 148 subjects with a phase 1 allocation of 3:3:2 to placebo:placebo:drug were required to attain 80% power with the two-sided test of the hypothesis at the 0.05 level. Participant retention between phases was assumed to be 85%.

For the second trial, assuming a difference of −2.0 in HAM-D score change between the treatment and placebo groups in both phases and standard deviations of reductions equal to 4.0 in both treatment arms and both phases (approximate pooled effect size of 0.35), 75 subjects with a phase 1 allocation of 3:3:2 to placebo:placebo:drug were required to attain 80% power with the two-sided test of the hypothesis at the 0.05 level. Placebo response in phase 1 was expected to be 25% and participant retention between phases 85%.

**Results**

**Trial 1**

In the first trial, 148 patients (103 [69.5%] of them women) were randomly assigned to treatment. The participants' mean age was 47.9 years (SD=11.6). Their mean baseline HAM-D score was 19.7 (SD=4.7). A total of 36 patients were assigned to the drug-drug sequence (7.5 mg/day of L-methylfolate in phase 1 and 15 mg/day in phase 2), 58 to the placebo-drug sequence (placebo in phase 1 and 7.5 mg/day of L-methylfolate in phase 2), and 54 to the placebo-placebo sequence (placebo in both phases 1 and 2). A total of 119 patients (80.0%) completed the study. All patients were taking an SSRI at the time of randomization and continued throughout the trial; 36 were on sertraline, 35 on escitalopram, 35 on fluoxetine, 32 on citalopram, and 10 on paroxetine. Efficacy analyses of phases 1 and 2 are reported in Table 1. Pooling of phases 1 and 2 for the two primary outcome measures is depicted in Figures 1 and 2.

As noted above, 7.5 mg/day of adjunctive L-methylfolate did not appear to result in a treatment outcome (efficacy) superior to continued SSRI therapy plus placebo in either phase of the study. However, patients who underwent an increase in dosage to 15 mg/day in phase 2 had a greater response rate than those who continued on SSRI therapy plus adjunctive placebo (24.0% compared with 9%), although the difference fell short of statistical significance (p=0.1).

Adverse events are reported in Table 2. There were no statistically significant differences in the change in weight, supine and standing heart rate, or supine and standing diastolic and systolic blood pressure between the L-methylfolate and placebo groups in phase 1 or 2.

**Trial 2**

Given the results in trial 1, the second trial used only 15 mg/day of L-methylfolate in the drug-drug and placebo-drug sequences. Seventy-five patients (53 [70.6%] of them women) were assigned to treatment as follows: 19 to the drug-drug sequence (15 mg/day of L-methylfolate in both phases 1 and 2), 28 to the placebo-drug sequence (placebo in phase 1 and 15 mg/day of L-methylfolate in phase 2), and 28 to the placebo-placebo sequence (placebo in both phases 1 and 2). The participants' mean age was 48.4 years (SD=12.1), and their mean baseline HAM-D score was 21.2 (SD=3.9). A total of 61 patients (81.3%) completed the study. Again, all participants were taking an SSRI at baseline and continued throughout the trial. Efficacy analyses of phases 1 and 2 are presented in Table 3. Pooling of phases 1 and 2 on the two primary outcome measures is depicted in Figures 1 and 2.
TABLE 1. Efficacy Results of the First of Two Trials of L-Methylfolate (MTFH) Compared With Placebo as an Adjunct to SSRIs in Patients With SSRI-Resistant Depression

<table>
<thead>
<tr>
<th>Measure</th>
<th>Phase 1 (30 Days)</th>
<th>Phase 2 (30 Days)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MTFH, 7.5 mg/day (N=36)</td>
<td>Placebo (N=112)</td>
</tr>
<tr>
<td>Completed treatment</td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>HAM-D</td>
<td>33</td>
<td>91.6</td>
</tr>
<tr>
<td>Response</td>
<td>7</td>
<td>19.4</td>
</tr>
<tr>
<td>Remission</td>
<td>4</td>
<td>11.1</td>
</tr>
<tr>
<td>Mean</td>
<td>SD</td>
<td>Mean</td>
</tr>
<tr>
<td>Baseline score</td>
<td>18.8</td>
<td>4.2</td>
</tr>
<tr>
<td>Score reduction</td>
<td>-4.3</td>
<td>5.0</td>
</tr>
<tr>
<td>CGI severity scale</td>
<td>20.7</td>
<td>5.2</td>
</tr>
<tr>
<td>Baseline score</td>
<td>4.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Score reduction</td>
<td>-0.5</td>
<td>1.0</td>
</tr>
</tbody>
</table>

a HAM-D=Hamilton Depression Rating Scale; CGI=Clinical Global Impressions scale. Treatment response was defined as a reduction of ≥50% in HAM-D or CGI score during treatment (or a final score of ≤7 on the HAM-D or ≤5 on the CGI-S) and remission was defined as a final score of ≤7 on the HAM-D or ≤5 on the CGI-S.

b According to the format of the sequential parallel comparison design model used in this study, only patients who completed phase 1 and did not achieve a treatment response (as indicated by the HAM-D) are analyzed in phase 2.

c Using the Fava et al. method (25) for dichotomous measures in sequential parallel comparison design analyses and the Tamhane and Huang method (30) for continuous measures.

FIGURE 1. Pooled Response Rates in Two Trials of L-Methylfolate (MTFH) Compared With Placebo as an Adjunct to SSRIs in Patients With SSRI-Resistant Depression

Response was defined as a reduction of ≥50% in Hamilton Depression Rating Scale score during treatment or a final score of ≤7. Significant difference between groups in trial 2 (p=0.04). The pooled analysis was conducted as described in Fava et al. (25).

In the second trial, 15 mg/day of adjunctive L-methylfolate appeared to result in a treatment outcome (efficacy) superior to continued SSRI therapy plus placebo in both primary outcome measures, achieving statistical significance at the 0.05 level both in the difference in response rates (32.3% compared with 14.6%, p=0.04) and in the difference in degree of improvement (-5.58 compared with -3.04, p=0.05) on the HAM-D. The results also suggested superior efficacy for L-methylfolate on two of the secondary outcome measures—change in score on the CGI-S (4.7 compared with -2.62, p=0.04) and on the CGI severity scale (-0.92 compared with -0.34, p=0.01).

Adverse events are reported in Table 4. There was no statistically significant difference in the change in weight, supine and standing heart rate, or supine and standing diastolic and systolic blood pressure between the L-methylfolate and placebo groups in phase 1 or 2. One patient in the L-methylfolate group was withdrawn from the trial because of the development of manic symptoms.

Discussion

This is the first report of randomized, double-blind, placebo-controlled trials involving the adjunctive use of L-methylfolate (at 7.5 mg/day and 15 mg/day) for patients with major depression who have responded only partially or not at all to SSRIs. To enhance statistical power, both studies used a novel sequential parallel comparison design (25). Results of both studies were informative about the use of L-methylfolate as adjunctive therapy in major depression. In the first trial, we found no difference between placebo and adjunctive L-methylfolate at 7.5 mg/day (administered for
FIGURE 2. Pooled Mean Reduction in Hamilton Depression Rating Scale Score in Two Trials of L-Methylfolate (MTHF) Compared With Placebo as an Adjunct to SSRIs in Patients With SSRI-Resistant Depression\(^a\)

<table>
<thead>
<tr>
<th></th>
<th>MTHF, 7.5 mg/day (N=143)</th>
<th>Placebo (N=143)</th>
<th>Side Effect Category</th>
<th>N</th>
<th>%</th>
<th>N</th>
<th>%</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial 1 (7.5 mg/day for 30 days)</td>
<td>17</td>
<td>89.4</td>
<td>33</td>
<td>9.6</td>
<td>10.0</td>
<td>10.0</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Trial 2 (15 mg/day for 30 days)</td>
<td>15</td>
<td>83.3</td>
<td>33</td>
<td>9.5</td>
<td>10.0</td>
<td>10.0</td>
<td>0.06</td>
<td></td>
</tr>
</tbody>
</table>

\(^a\) Significant difference between groups in trial 2 (p<0.05). The pooled analysis was conducted as described in Tamura and Huang (30).

TABLE 3. Efficacy Results of the Second of Two Trials of L-Methylfolate (MTHF) Compared With Placebo as an Adjunct to SSRIs in Patients With SSRI-Resistant Depression

<table>
<thead>
<tr>
<th>Measure(^a)</th>
<th>MTHF, 15 mg/day (N=19)</th>
<th>Placebo (N=56)</th>
<th>Pooled MTHF(^c)</th>
<th>Pooled Placebo(^c)</th>
<th>p(^d)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed treatment</td>
<td>17</td>
<td>89.4</td>
<td>50</td>
<td>89.2</td>
<td></td>
</tr>
<tr>
<td>HAM-D</td>
<td>7</td>
<td>36.9</td>
<td>11</td>
<td>19.6</td>
<td>5</td>
</tr>
<tr>
<td>Remission</td>
<td>3</td>
<td>15.7</td>
<td>7</td>
<td>12.5</td>
<td>2</td>
</tr>
<tr>
<td>Baseline score</td>
<td>21.2</td>
<td>4.1</td>
<td>21.2</td>
<td>3.2</td>
<td>19.5</td>
</tr>
<tr>
<td>Score reduction</td>
<td>-7.5</td>
<td>5.5</td>
<td>-4.4</td>
<td>5.8</td>
<td>-3.8</td>
</tr>
<tr>
<td>QIDS-SR</td>
<td>N</td>
<td>%</td>
<td>N</td>
<td>%</td>
<td>N</td>
</tr>
<tr>
<td>Response</td>
<td>7</td>
<td>36.8</td>
<td>12</td>
<td>21.4</td>
<td>2</td>
</tr>
<tr>
<td>Remission</td>
<td>4</td>
<td>21.0</td>
<td>1</td>
<td>1.7</td>
<td>1</td>
</tr>
<tr>
<td>Baseline score</td>
<td>15.7</td>
<td>5.8</td>
<td>17.2</td>
<td>5.5</td>
<td>17.3</td>
</tr>
<tr>
<td>Score reduction</td>
<td>-8.1</td>
<td>5.3</td>
<td>-5.7</td>
<td>5.6</td>
<td>-1.3</td>
</tr>
<tr>
<td>CGI severity scale</td>
<td>4.6</td>
<td>0.6</td>
<td>4.4</td>
<td>0.6</td>
<td>4.0</td>
</tr>
<tr>
<td>Score reduction</td>
<td>-1.3</td>
<td>0.9</td>
<td>-0.6</td>
<td>1.0</td>
<td>-0.5</td>
</tr>
</tbody>
</table>

\(^a\) HAM-D=Hamilton Depression Rating Scale; QIDS-SR=Quick Inventory of Depressive Symptomatology-Self-Rated; CGI=Clinical Global Impression scale. Treatment response was defined as a reduction of ≥50% in HAM-D or QIDS-SR score during treatment (or a final score of ≥7 on the HAM-D or ≥5 on the QIDS-SR) and remission was defined as a final score of ≤7 on the HAM-D or ≤5 on the QIDS-SR.

\(^b\) According to the format of the sequential parallel comparison design model used in this study, only patients who completed phase 1 and did not achieve a treatment response as indicated by the HAM-D are analyzed in phase 2.

\(^c\) Using the Fava et al. method (25) for dichotomous measures in sequential parallel comparison design analyses and the Tamura and Huang method (30) for continuous measures.

up to 30 days; however, among patients who experienced no response with 7.5 mg/day, the response rate and change in depression symptom score were greater than among those who continued on SSRI therapy plus placebo, although the difference did not reach statistical significance. The latter finding informed our design of the second trial, which was identical to the first trial except that all patients treated with adjunctive L-methylfolate received 15 mg/day.

The results of the second trial indicated greater efficacy for 15 mg/day of adjunctive L-methylfolate (administered for up to 30 days) with continued SSRI therapy compared with continued SSRI therapy plus placebo on both primary outcome measures. These results suggest that 15 mg/day of L-methylfolate can be a useful adjunctive treatment strategy for patients with major depression who have not responded to SSRIs. The number needed to treat
TABLE 4. Adverse Events Reported in the Second of Two Trials of l-Methylfolate (MTFH) Compared With Placebo as an Adjunct to SSRIs in Patients With SSRI-Resistant Depression

<table>
<thead>
<tr>
<th>Side Effect Category</th>
<th>Placebo (N=54)</th>
<th>MTFH, 15 mg/day (N=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>%</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>8</td>
<td>14.8</td>
</tr>
<tr>
<td>Sleep</td>
<td>3</td>
<td>5.5</td>
</tr>
<tr>
<td>Psychological</td>
<td>9</td>
<td>16.7</td>
</tr>
<tr>
<td>Somatic</td>
<td>16</td>
<td>29.6</td>
</tr>
<tr>
<td>Infectious</td>
<td>7</td>
<td>13.0</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Sexual</td>
<td>0</td>
<td>0.0</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>5</td>
<td>9.3</td>
</tr>
</tbody>
</table>

*Ns are based on the total numbers of patients who received placebo or 15 mg of l-methylfolate, respectively, at some point during the trial.

Similar or different outcomes than 15 mg/day is unclear. Furthermore, these trials excluded certain populations of patients (children and adolescents; patients with bipolar disorder, psychotic major depression, active substance use disorders, or unstable axis III comorbid illness; and women with perinatal depression). Further studies are needed to examine whether 15 mg/day of l-methylfolate would be efficacious in these patient populations as well. A final limitation concerns the fact that these trials did not utilize a standard parallel comparison design, but instead used the sequential parallel comparison design, a novel study design that enhances statistical power in randomized clinical trials (34, 35). However, the effects noted with the sequential parallel comparison design are certainly consistent with those noted in phase 1 of the study and therefore typical of a standard design.

In summary, our results suggest that 15 mg/day, but not 7.5 mg/day, of adjunctive l-methylfolate may constitute an effective, safe, and relatively well tolerated augmentation strategy for patients with major depression who have had no response or a partial response to SSRIs. Replication of these results in an independent cohort is needed, as well as additional research to further clarify the antidepressant role of l-methylfolate and other elements of the one-carbon cycle.

Received July 25, 2011; revisions received March 12 and July 2, 2012; accepted July 16, 2012. doi: 10.1176/appi.ajp.2012.11071114

From the Center for Treatment-Resistant Depression, Depression Clinical and Research Program, the Biostatistics Center, and the Clinical Trials Network and Institute, Massachusetts General Hospital, Boston; Harvard Medical School, Boston; the Harvard Clinical Research Institute, Boston; the Department of Biostatistics, Boston University, Boston; the Department of Psychiatry, Vanderbilt University School of Medicine, Nashville; Rush University Medical Center, Chicago; the Department of Psychiatry, University of Pennsylvania, Philadelphia; Baylor Research Institute, Institute of Metabolic Disease, Dallas; the Department of Psychiatry, University of Cincinnati Academic Health Center, Cincinnati; the Louisiana State University Health Sciences Center, New Orleans; the Department of Psychiatry, University of California San Diego; and San Diego VA Healthcare Service. Address correspondence to Dr. Papakostas (gpapakostas@partners.org).

Dr. Papakostas has received research support from, served as a consultant or speaker for, or received honoraria for CME activities for Abbott, AstraZeneca, Brainway, Bristol-Myers Squibb, Cephalon, Dey Pharma, Eli Lilly, Forest, GlaxoSmithKline, Lundbeck, NIH, Otsuka, Pamlab, Ridge Diagnostics, Roche, Takeda, Theracos, and Sunovion. Dr. Shelton has received research support or served as a consultant for Bristol-Myers Squibb, Eli Lilly, Cyberonics, Elan, Euthymics Bioscience, Forest, Janssen Pharmaceutica, Medtronic, Novartis, Otsuka, Pamlab, Pfizer, Repligen, Ridge Diagnostics, Takeda Pharmaceuticals, and St. Jude Medical. Dr. Zajecka has received research support from or served as a consultant, advisor, or speaker for Abbott, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, Hoffman-LaRoche, McNeil, Novartis, Otsuka, Pamlab, Pfizer, Shire, and Takeda. Dr. Schoenfeld is a patent holder for the sequential parallel design used in this study; the patent is owned by his employer, Massachusetts General Hospital. Dr. Pencina has served as a consultant for Pamlab and RCT Logic. Ms. Meiner has served as a consultant for Massachusetts General Hospital and Pamlab, has received a grant from the National Heart, Lung and Blood Institute, and has received funds.
from grants at the Harvard School of Public Health. Dr. Botlgieri has received research support from and has served as a consultant for Pamlab, has served as the chairman of the advisory board for Methylation Sciences, and holds stock options in Methylation Sciences. Dr. Nelson has received research support from AstraZeneca, Eli Lilly, GlaxoSmithKline, and Pamlab. Dr. Mischoou has received research support or honoraria for consulting, speaking, and writing from the Bowman Family Foundation, Bristol-Myers Squibb, Cederroth, FischerWallace, Geneden, Lichter Pharma, Nordic Naturals, and Pamlab and has received royalties from Back Bay Scientific and Lippincott Williams & Wilkins. Dr. Alpert has received research support from or served as an adviser, consultant, or speaker for Abbott, Alkermes, APA, Lichter Pharma, Loxex, Aspect Medical Systems, AstraZeneca, Bristol-Myers Squibb, Cephalon, Cyberonics, Eli Lilly, Forest, GlaxoSmithKline, J & J Pharmaceuticals, MGH Psychiatry Academic/Reed Medical Education, MGH Psychiatry Academy/Prime Media, Novartis, Organon, Pamlab, Pfizer, Pharmavive, Roche, Sanofi/ Synthelabo, Solvay, Wyeth-Ayerst, and Xian-Janssen and has received editorial fees from Belvoir Publishing. Dr. Barbee has received research support from or served as a speaker for AstraZeneca, Bristol-Myers Squibb, Dey Pharmaceuticals, Eli Lilly, Forest, Merck, Pfizer, and Sheppard Pratt Health System and has done forensic consulting work for various attorneys. Dr. Zisook has received research support from Pamlab. Dr. Davila has received support from Abbott, Alkermes, Aspect Medical Systems, AstraZeneca, BioResearch, BrainCells, Bristol-Myers Squibb, Cephalon, BioPharma, Clinical Trials Solutions, Clintara, Covidien, Eli Lilly, EnVivo Pharmaceuticals, Euthymics Bioscience, Forest, Genaden Biotech, GlaxoSmithKline, Icon Clinical Research, 13 Innovus, Johnson & Johnson Pharmaceutical Research and Development, Lichter Pharma, Loxex Pharmaceuticals, NARSAD, National Center for Complementary and Alternative Medicine, National Institute on Drug Abuse, NIH, Novartis, Organon, Pamlab, Pfizer, Pharmavive, Photothera, Roche, RCT Logic, Sanofi-Aventis, Shire, Solvay, Synthelabo, and Wyeth-Ayerst; he has served as an adviser or consultant (unpaid except as otherwise noted) for Abbott Laboratories, Afectis Pharmaceuticals, Alkermes, Amneal Pharmaceuticals, Aspect Medical Systems, AstraZeneca, Auspex Pharmaceuticals, Bayer, Best Practice Project Management, BioMarin Pharmaceuticals, Biovail, BrainCells, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Clinical Trials Solutions, CNS Response, Compellis Pharmaceuticals, Cypress Pharmaceutical, DiagnoseSearch Life Sciences, Dinson Sumitomo Pharma, Dov Pharmaceuticals, Edgemont Pharmaceuticals, Elsai, Eli Lilly, ePharmaSolutions, EPiK Pharmaceuticals, Euthymics Bioscience, Fable, Kramer, Forest, Genomind, GlaxoSmithKline, Grunenthal, 13 Innovus, Janssen Pharmaceutica, Jazz Pharmaceuticals, Johnson & Johnson Pharmaceutical Research and Development (remunerated), Kolln Pharmaceuticals, Labopharm, Lorax Pharmaceuticals, Lundbeck, Med-avante, Merck, MBI Methylation Sciences, Naurex, Neurotensics, Novartis, Nutrilite, 21, Orexin Therapeutics, Organon, Organon Kata, Pamlab, Pfizer, PharmaStar, Pharmavive, PharmoRx Therapeutics, Precision Human Biobalancing, Presa Pharmaceuticals, Puretech Ventures, Psychogenics, Psylin Neurosciences, Rexahn Pharmaceuticals, Ridge Diagnostics, Roche, RCT Logic, Sanofi-Aventis, Sepracor, Servier Laboratories, Schering-Plough, Solvay, Somaxon, Somerset Pharmaceuticals, Sunovion, Synthelabo, Takeda, Tegretol, Tegretol, TransForm Pharmaceuticals, Transcept Pharmaceuticals, and Vanda Pharmaceuticals; he has provided speaking/publishing (unpaid except as otherwise noted) for Adamed, Advanced Meeting Partners, APA, American Society of Clinical Psychopharmacology, AstraZeneca, Belvoir Media Group (remunerated), Boehringer Ingelheim, Bristol-Myers Squibb, Cephalon, CME Institute/Physicians Postgraduate Press (remunerated), Eli Lilly, Forest, GlaxoSmithKline, Imesides, MGH Psychiatry Academy/Prime Media, MGH Psychiatry Academy/Reed Elsevier (remunerated), Novartis, Organon, Pfizer, PharmaStar, United BioSource, and Wyeth-Ayerst; he has equity holdings in Compellis; he is a patent holder for the sequential parallel design used in this study (the patent is owned by Massachusetts General Hospital) and has a patent application for a combination of ketamine and scopolamine in major depression; and he receives royalties from Lippincott Williams & Wilkins. The other authors report no financial relationships with commercial interests.

Both trials were funded by Pamlab.

Clinicaltrials.gov identifiers: NCT00321152 and NCT00955955.

The authors acknowledge Dr. Bruce Lydiard for his role as a site principal investigator in this study.

References


This publication has been compiled by Content Ed Net, LLC, under license from the publisher. Though great care has been taken in compiling the contents of this publication, the American Psychiatric Association and Content Ed Net, LLC are not responsible or in any way liable for the currency of the information, for any errors, omissions, inaccuracies or for any consequences arising there from approved product information should be reviewed before prescribing.